AnalystsEva Fortea Verdejo
Eva Fortea Verdejo's Stock Forecasts

Sectors:
Industries:
Analyst Ranking
Top 5%
#234 out of 5515 analysts
Average Return
+51.97%
Win Rate
80%33 out of 41
Risk vs Reward
Poor
Good

Eva Fortea Verdejo's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Revolution Medicines IncRVMD
+339.77%$46.24$203.35
2025-09-11 -
2026-09-10
Strong Buy
Xencor IncXNCR
+173.22%$7.32$20.00
2025-08-07 -
2026-08-06
Strong Buy
Arcus Biosciences IncRCUS
+149.19%$8.01$19.96
2025-05-07 -
2026-02-12
Strong Buy
Relay Therapeutics IncRLAY
+134.62%$8.03$18.84
2025-12-12 -
2026-09-18
Strong Buy
Merus NvMRUS
+127.08%$41.25$93.67
2025-02-07 -
2025-09-29
Strong Buy

Eva Fortea Verdejo's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Bicara Therapeutics IncBCAX
5Hold$23.00+1.59%Maintains
a month ago
Zymeworks IncZYME
7Strong Buy$40.00+50.55%Maintains
a month ago
Arcus Biosciences IncRCUS
6Hold$26.00+3.01%Maintains
a month ago
Exelixis IncEXEL
3Hold$49.00-16.04%Maintains
2 months ago
Kiniksa Pharmaceuticals International PLCKNSA
6Strong Buy$74.00-4.19%Maintains
2 months ago
Nuvalent IncNUVL
2Hold$124.00+0.03%Downgrades
3 months ago
Celcuity IncCELC
2Strong Buy$166.00+105.93%Maintains
4 months ago
Relay Therapeutics IncRLAY
5Strong Buy$21.00+11.46%Maintains
5 months ago
Revolution Medicines IncRVMD
3Strong Buy$167.00-12.54%Maintains
5 months ago
Ideaya Biosciences IncIDYA
2Strong Buy$48.00+24.97%Maintains
5 months ago
Sutro Biopharma IncSTRO
1Strong Buy$27.00+76.01%Upgrades
6 months ago
Genmab AGMAB
1Strong Buy$40.00+15.14%Initiates Coverage On
7 months ago
Immunocore Holdings PLCIMCR
1Strong Buy$60.00+87.50%Initiates Coverage On
a year ago
Merus NvMRUS
5Hold$97.00+7.78%Downgrades
a year ago
Iteos Therapeutics IncITOS
7Hold$11.00N/AMaintains
a year ago
Xencor IncXNCR
3Strong Buy$27.00N/AMaintains
a year ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.